Femke M. de Man

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16

Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions

Roelof W. F. van Leeuwen, Frank G. A. Jansman, Patricia M. L. A. van den Bemt et al. · Annals of Oncology · 2015 · 142 citations · Full text

Medicine, Oncology, Pharmacology +16

A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · European Journal of Cancer · 2018 · 90 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study

Mirjam de With, Jonathan E. Knikman, Femke M. de Man et al. · Clinical Pharmacology & Therapeutics · 2022 · 56 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +14

Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis

Jonathan E. Knikman, Tycho A. Wilting, Marta López‐Yurda et al. · Journal of Clinical Oncology · 2023 · 55 citations · Full text

Medicine, Oncology, Pharmacology +16